GEA opens factory in India
Vadodara, Gujarat factory provides local build of processing equipment
Until now GEA Pharma Systems, the technology leader in pharmaceutical processing, has manufactured outside India, mainly in Europe. The new factory will offer strategic low-cost manufacturing, allowing the company to provide European-quality processing equipment at prices that are affordable in the growing Indian market.
‘India is a high-growth market that’s very price-sensitive and susceptible to technology,’ said Navin Lakhanpaul, regional manager for GEA Pharma Systems in Vadodara. ‘This low-cost manufacturing base will allow us to provide the high-end, European quality products our Indian customers need at prices that are appropriate to the local market.’ He added that the local manufacture will also help the company be more reactive to local market demands.
The factory will employ local staff and peripheral equipment, such as control systems, will also be sourced locally, providing an additional boost to local suppliers. ‘In most projects, much of the project value is in peripheral equipment. It’s also essential for us to keep the technical know-how close at hand to help us maintain the efficient after-sales service our customers expect,’ said Navin.
The effects of low-cost manufacturing, locally-sourced peripheral equipment and reduced transportation costs can often reduce the equipment price significantly when compared with equipment bought from Europe.
Navin also explained that the high quality approach satisfied the demand for all pharmaceutical equipment produced in India to meet international quality standards. ‘Not only do our Indian customers want to supply the local market with high-quality products they also want the facilities necessary to sell into Europe and offer manufacturing services to European customers. Our equipment provides the necessary quality, efficiency and environmental control to allow them to do so.’
Frans Maas, GEA Pharma Systems’ division director for sales and marketing, commented that the new facility was critical to the organisation’s long-term plans. ‘The factory in Vadodora is an important development for our company and part of our strategy for sustainable supply,’ he explained. The opening of the factory, for example, follows soon after GEA’s announcement of two agency agreements with ACE Technologies of Mumbai, for the distribution of MODUL tablet presses from GEA Courtoy and pharmaceutical freeze drying technology from GEA Lyophil throughout India.
The factory has been built adjacent to the company’s existing office building which was opened in 2007.
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
Read moreAt Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology